-
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…
-
Statera BioPharma: The Ticker Formerly Known as CBLI
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases. The company began trading as CLBI, last month,…
-
Financial Transparency is Key to Any Relationship, Financial Infidelity Being the Ultimate Killer
Previously Published on News Break Whether running a tight ship or planning for a post-pandemic wedding of the century, couples are, for the most part, always coming up with new ways to manage their money. Despite an imminent fear of catching the coronavirus, a record number of professionals have become hyper-focused on advancing their careers — some on the brink of unemployment while others are possibly even losing their businesses due to shutdown and quarantine. “How did the pandemic change the way couples ‘do money’ together?” This was something Policygenius really wanted to know. The nation’s leading online insurance marketplace conducted a survey by polling more than 1,500 adults across…
-
Tech Leaders Make a Bold Statement, Predicts These Companies Will Undoubtedly Fail in Three Years or Less
Previously Published to News Break One year into the pandemic and our world is becoming the ultimate ghost town. We’re seeing a massive exodus from the West Coast, businesses closing doors, and workers being laid off in numbers from those that had never been laid off before. Tech says there’s an app for that but so many fail to listen! In an annual Kong survey, more than 400 senior technology decision-makers were polled across a broad range of US and European industries, the general consensus was that if businesses refused to modernize, they’d be next to be featured in the Smithsonian. According to the 2021 Digital Innovation Benchmark report, 51%…
-
Who relocates during a pandemic? | Robert Half reveals new trends in the Jobs Industry
Previously Published on News Break In case you haven’t noticed, our economy has been re-opening since the introduction of vaccines. People are traveling again. Others are looking for work. And, hiring managers are back on the scene, recruiting for their latest openings — yet, so much of our regular hiring processes have changed. Last month, one company reported that more than 29% of working professionals would quit their job if not allowed to continue working remotely and that 62% of long-term employees preferred employers that offered work from home opportunities in the future. Most have reported that working from home made them more productive, allowed them to focus on quality…
